Pharmaron released its interim results, with a profit attributable to shareholders of 701 million yuan, a year-on-year decrease of 37%
Pharmaron released its interim results for the period ending June 30, 2025, with revenue of 6.441 billion yuan, a year-on-year increase of 14.93%; profit attributable to shareholders was 701 million yuan, a year-on-year decrease of 37%. The basic earnings per share were 0.3984 yuan. The company stated that although the main business continued to improve, the net profit decreased by 37% compared to the same period last year due to significant investment gains from the disposal of PROTEOLOGIX, INC. shares in the previous year
According to the Zhitong Finance APP, Pharmaron (03759) announced its interim results for the six months ending June 30, 2025, with revenue of 6.441 billion yuan (RMB, the same below), an increase of 14.93% year-on-year; profit attributable to shareholders was 701 million yuan, a decrease of 37% year-on-year; basic earnings per share were 0.3984 yuan.
The announcement stated that under the continued improvement of the main business, the company achieved a net profit attributable to shareholders of the listed company of 701 million yuan during the reporting period, mainly due to the significant investment income generated from the disposal of PROTEOLOGIX, INC. shares in the same period last year, which decreased by 37.0% compared to the same period last year
